Search results
Elementis shareholder Gatemore calls for strategic review
ShareCast· 4 days agoElementis shareholder Gatemore Capital Management said on Tuesday that if the company does not...
Judges Scientific snaps up geological analysis firm Rockwash
ShareCast· 1 day agoScientific instruments group Judges Scientific has spent £2.25m on the purchase of Wales-based Rockwash Geodata, a specialist in rock cuttings and chippings digitalisation.
Europe open: Shares up as UK GDP rises; Eyes on US data later
ShareCast· 1 day agoEuropean shares were higher at the open on Friday as investors digested stronger-than-expected UK GDP figures and awaited US inflation figures later in the day. Investors now look towards the ...
Asia report: Markets higher despite rise in Aussie inflation
ShareCast· 3 days agoMarkets in the Asia-Pacific region were mostly in the green on Wednesday, as chip stocks followed...
Chemring appoints Tony Wood as its next chairman
ShareCast· 5 days agoChemring Group announced the appointment of Tony Wood as an independent non-executive director and chairman-designate on Monday. Carl-Peter Forster, who...
Warpaint reports robust trading in first half
ShareCast· 3 days agoCosmetics supplier Warpaint London, owner of the W7 and Technic brands, reported a robust trading performance ahead of its annual general meeting on...
German sentiment unexpectedly dips as recovery stalls
ShareCast· 3 days agoA closely followed gauge of consumer sentiment in Germany unexpectedly fell further into negative...
Jefferies double upgrades Future to ‘buy’, shares surge
ShareCast· 3 days agoFuture surged on Wednesday as Jefferies upgraded the shares to ‘buy’ from ‘underperform’ and hiked...
Symphony reports consistent trading as it works to accelerate projects
ShareCast· 1 day agoSymphony Environmental Technologies said in an update on Friday that its trading remained consistent with recent statements.
AstraZeneca posts mixed results from recent Imfinzi trials
ShareCast· 4 days agoAstraZeneca announced contrasting results from two phase three trials involving its immunotherapy...